Clopidogrel Hypersensitivity: A Novel Multi-Day Outpatient Oral Desensitization Regimen

Abstract

Spanish

French

BACKGROUND

Clopidogrel hypersensitivity has posed a problem for the acute treatment and long-term care of a particular patient population with coronary artery disease and stent placement. Patients with clopidogrel hypersensitivity have had an increased risk of hypersensitivity reactions, including anaphylaxis, if they ingest clopidogrel without undergoing an oral desensitization procedure. The previously published desensitization protocols have either been performed in the intensive care unit, requiring significant cost and healthcare utilization, or have required a full-day outpatient commitment on behalf of the patient.

OBJECTIVE

To determine whether a multi-day outpatient oral clopidogrel desensitization protocol is effective and safe for patients with clopidogrel hypersensitivity.

METHODS

gWe retrospectively assessed the efficacy of a 10-dose outpatient multiday clopidogrel desensitization protocol performed in a university allergy-immunology center from April 2006 to October 2008 in patients with clopidogrel hypersensitivity. Patients were desensitized over 2–3 half-day clinical visits and were able to go home between desensitization sessions. A preliminary cost analysis was performed using the average of actual costs for the outpatient clopidogrel desensitization procedure and was compared with the average cost for an inpatient oral desensitization completed at our institution.

RESULTS

Eight patients with coronary artery disease, cardiac stent placement, and clopidogrel hypersensitivity underwent an outpatient multi-day oral clopidogrel desensitization procedure. All patients were successfully desensitized with the multi-day protocol without complications. No patient had recurrence of allergic reaction 3 months after the procedure. A preliminary cost analysis demonstrated a lower cost for the outpatient compared to the inpatient oral clopidogrel desensitization protocol.

CONCLUSIONS

This outpatient 10-dose multi-day clopidogrel desensitization protocol is a safe and effective novel approach for the treatment of clopidogrel hypersensitivity in patients with coronary artery disease and cardiac stent placement. In addition to safety and efficacy, this protocol offers the patient the convenience of avoiding hospital admission or full-day time commitments.

Keywords

cardiac stent treatment clopidogrel hypersensitivity drug desensitization

Get full access to this article

View all access options for this article.

References

1. Grines

Bonow

Casey

Jr ; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813–8. Epub 15 Jan 2007. DOI 10.1161/CIRCULATIONAHA.106. 180944.

2. Becker

Meade

Berger

, American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:776S–814S. DOI 10.1378/chest.08-0685.

3. Pinto Slottow

Steinberg

Roy

Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008;102:298–303. Epub 29 May 2008. DOI 10.1016/j.amjcard.2008.03.055.

4. Product information. Plavix (clopidogrel bisulfate). New York, NY: Bristol-Myers Squibb Company & Sanofi-Synthelabo, August 2008.

5. Nebeker

Virmani

Bennett

Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175–81. Epub 1 Dec 2005. DOI 10.1016/j.jacc.2005.07.071.

6. Walker

Fasano

Horwitz

PA.

Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. J Invasive Cardiol 2006;18:341–4.

7. Khambekar

Kovac

Gershlick

AH.

Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart 2004;90:e14–6. DOI 10.1136/hrt.2003.027367.

8. Lee-Wong

Gadhvi

Resnick

Clopidogrel desensitization (letter). Ann Allergy Asthma Immunol 2006;96:756–7.

9. Camara

Almeda

FQ.

Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005;65:525–7. DOI 10.1002/ccd.20433.

10.

10. Gowda

Misra

Khan

IA.

Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose (letter). Int J Cardiol 2004;95: 333. DOI 10.1016/j.ijcard.2003.03.023.

11.

11. Sarrot-Reynauld

Bouillet

Bourrain

JL.

Severe hypersensitivity associated with clopidogrel (letter). Ann Intern Med 2001;135:305–6.

12.

12. Makkar

Wilensky

Julien

Herrmann

Spinler

SA.

Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother 2006;40:1204–7. Epub 9 May 2006. DOI 10.1345/aph.1G587.

13.

13. Satish

Tressa

Harish

CR.

Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent. Crit Pathw Cardiol 2007; 6:24–5. DOI 10.1097/01.hpc.0000255061.30935.f4.

14.

14. Fischer

Worm

Groneberg

DA.

Clopidogrel-associated angioedema (letter). Am J Med 2003;114:77–8. DOI 10.1016/S0002-9343(02)01311-6.

15.

15. Andres

Perrin

Alt

Goichot

Schlienger

JL.

Febrile pancytopenia associated with clopidogrel. Arch Intern Med 2001;161:125. DOI 10.1001/archinte.161.1.125.

16.

16. Doogue

Begg

Bridgman

Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005;80:1368–70. DOI 10.4065/80.10.1368.

17.

17. Andersohn

Hagmann

Garbe

Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004;90:e57–9. DOI 10.1136/hrt.2004.039214.

18.

18. Manor

Guillory

Jain

SP.

Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy 2004;24:664–7. DOI 10.1592/phco.24.6.664.34732.

19.

19. Moy

Wang

Raffel

Marcoux

2nd. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med 2000;160:1370–2. DOI 10.1001/archinte.160.9.1370.

20.

20. Chinnakotla

Leone

Fidler

Hammeke

Tarantolo

Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. Transplantation 2000;70:550–2. DOI 10.1097/00007890-200008150-00029.

21.

21. Camara

Almeda

FQ.

Clopidogrel (Plavix) desensitization protocol (letter). Catheter Cardiovasc Interv 2007;69:154. DOI 10.1002/ccd.20919.

22.

22. Owen

Garner

Hergott

Page

RL II.

Clopidogrel desensitization: case report and review of published protocols. Pharmacotherapy 2008;28:259–70. DOI 10.1592/phco.28.2.259.

23.

23. Oppedijk

Odekerken

van der Wildt

Melissant

CF.

Rapid oral desensitisation procedure in clopidogrel hypersensitivity. Neth Heart J 2008;16:21–3.

24.

24. Walker

Fasano

Hobbs

Horwitz

PA.

Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Crit Pathw Cardiol 2007;6:26–9. DOI 10.1097/01.hpc.0000256476.82317.77.

25.

25. Kammer

RT.

Successful clopidogrel desensitization after drug-eluting stent implantation. J Invasive Cardiol 2009;21:134–5.

26.

26. Vigo

MacDowell

Wedner

HJ.

Successful desensitization with clopidogrel after a positive skin test (abstract 44). Ann Allergy Asthma Immunol 2005;94:132–3.

27.

27. von Tiehl

Price

Valencia

Ludington

Teirstein

Simon

RA.

Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007;50:2039–43. DOI 10.1016/j.jacc.2007.08.016.

28.

28. Celik

Pichler

Adkinson

Jr. Drug allergy. In: Adkinson

Jr Yunginger

Busse

, eds. Middleton's allergy: principles and practice. 7th ed. Philadelphia: Elsevier Inc., 2008:1205–26.

29.

29. Turvey

Cronin

Arnold

Dioun

AF.

Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004;92:426–32. DOI 10.1016/S0091-6749(03)81035-7.

30.

30. Gruchalla

RS.

Acute drug desensitization. Clin Exp Allergy 1998;28(S4):63–4.

31.

31. Gruchalla

Pirmohamed

Clinical practice. Antibiotic allergy. N Engl J Med 2006;354:601–9.

32.

32. Lokhandwala

Best

Butterfield

Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv 2009;2:348–51. DOI 10.1161/CIRCINTERVENTIONS.108.832964.108.832964.

33.

33. Product information. Effient (prasugrel). Indianapolis: Eli Lilly and Co., July 2009.

34.

34. Bhatt

DL.

Prasugrel in clinical practice. N Engl J Med 2009;361:940–2. DOI 10.1056/NEJMp0806848.

35.

35. Morrow

Wiviott

White

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758–64. DOI 10.1161/ CIRCULATIONAHA.108.833665.

36.

36. Hannaway

Hopper

GD.

Severe anaphylaxis and drug-induced betablockade (letter). N Engl J Med 1983;308:1536.

37.

37. Toogood

JH.

Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988;81:1–5. DOI 10.1016/0091-6749(88)90212-6.

38.

38. Lang

Alpern

Visintainer

Smith

ST.

Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 1991;115:270–6.

39.

39. Lang

DM.

Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf 1995;12:299–304. DOI 10.2165/00002018-199512050-23102.

40.

40. Goddet

Descatha

Liberge

Paradoxical reaction to epinephrine induced by beta-blockers in an anaphylactic shock induced by penicillin. Eur J Emerg Med 2006;13:358–60. DOI 10.1097/01.mej.0000217993.09364.35.

41.

41. Product information. Clopidogrel oral suspension. Nashville, TN: Vanderbilt University Hospital Prescription Compounding Centers of America (PCAA), January 2003.

42.

42. Campbell

Mallya

Jaffrani

Treatment of clopidogrel hypersensitivity without drug interruption. Presented at: 58th Scientific Sessions. American College of Cardiology, 2009.

43.

43. Adkinson

Jr. Desensitization for drug hypersensitivity. J Allergy Clin Immunol 2008;122:581–2. DOI 10.1016/j.jaci.2008.07.020.

44.

44. Solensky

Drug desensitization. Immunol Allergy Clin N Am 2004;24:425–43. DOI 10.1016/j.iac.2004.03.008.

45.

45. Tillman

Charland

Witt

DM.

Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926–32. DOI 10.1001/archinte.160.19. 2926.

46.

46. Spyropoulos

Hurley

Ciesla

de Lissovoy

Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108–14. DOI 10.1378/chest. 122.1.108.

47.

47. Huse

Cummins

Taylor

Russell

MW.

Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Am J Manag Care 2002;8(1 suppl):S10–6.

48.

48. Spyropoulos

Frost

Hurley

Roberts

Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004;125:1642–50. DOI 10.1378/chest.125.5.1642.

49.

49. Wai

Frighetto

Marra

Chan

Jewesson

PJ.

Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics 2000;18:451–7. DOI 10.2165/00019053-200018050-23104.

50.

50. Yong

Fisher

Sklar

SC.

A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents 2009;33:46–51. DOI 10.1016/j.ijantimicag.2008.07.016.